Clinical management of a patient following a granulocyte transfusion from a donor positive for COVID-19.
Jennifer S WooLefan ZhuangRyan JacksonShirong WangVaibhav AgrawalAmanda BlackmonHoda PourhassanShan YuanPublished in: Laboratory medicine (2024)
Granulocyte transfusions are indicated for patients with severe neutropenia and evidence of bacterial or fungal infection who are unresponsive to standard antimicrobial therapy. With a limited expiration time of 24 hours after collection, granulocytes are often transfused before results of infectious-disease screening tests are available, and before a transfusion service can perform a risk assessment if postdonation information is provided after the collection. The case we describe herein demonstrates a clinical scenario meeting indications for granulocyte transfusion, coupled with the clinical management undertaken after the granulocyte donor disclosed a positive result for a COVID-19 self-test taken 1 day after donation. In this case, the patient did not develop new COVID-19 symptoms and tested negative for COVID-19 after transfusion of the implicated unit. These findings add to the body of evidence in the literature that COVID-19 is not transmitted via blood transfusion.
Keyphrases
- coronavirus disease
- sars cov
- cardiac surgery
- risk assessment
- peripheral blood
- respiratory syndrome coronavirus
- case report
- systematic review
- mental health
- stem cells
- recombinant human
- acute kidney injury
- infectious diseases
- health information
- physical activity
- early onset
- mesenchymal stem cells
- social media
- bone marrow
- climate change
- red blood cell
- sleep quality